admin – Page 364 – Get News Story

Presbyopia Clinical Trial Pipeline Gains Momentum: 6+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Presbyopia Pipeline Insight 2026” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Presbyopia pipeline landscape. It covers the Presbyopia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Presbyopia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Presbyopia Pipeline @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight

Key Takeaways from the Presbyopia Pipeline Report

In March 2026- Ocuphire Pharma Inc. initiated a Phase 3 Study of the Safety and Efficacy of Nyxol (Phentolamine Ophthalmic Solution 0.75%) as a Single Agent and With Adjunctive Low-Dose Pilocarpine Hydrochloride Ophthalmic Solution 0.4% in Subjects With Presbyopia
DelveInsight’s Presbyopia Pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Presbyopia treatment.
The leading Presbyopia Companies such as Viatris, Glaukos Corporation, Tenpoint Therapeutics, Vyluma and others.
Promising Presbyopia Pipeline Therapies such as Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Pilocarpine HCl, UNR844-Cl, CSF-1, AGN-190584, Pilocarpine Ophthalmic, Aceclidine, Brimonidine and others.

Get insights into clinical trials, emerging therapies, and leading companies with Presbyopia @ Presbyopia Treatment Drugs

The Presbyopia Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Presbyopia Pipeline Report also highlights the unmet needs with respect to Presbyopia.

Presbyopia Overview

Presbyopia is a common, age-related refractive condition that leads to the gradual decline in the eye’s ability to focus on near objects, typically becoming noticeable in the early to mid-40s and continuing to progress with age. The condition primarily arises from age-induced changes in the crystalline lens, which loses its elasticity and becomes thicker due to protein cross-linking and compaction. This reduction in lens flexibility impairs its ability to change shape effectively during accommodation, a process that enables the eye to focus on nearby objects. Additionally, the ciliary muscle, responsible for exerting pressure on the lens to adjust its curvature, weakens with age, further limiting the eye’s capacity to focus on close-up tasks. While presbyopia is a natural and physiological part of the aging process, it can significantly affect an individual’s quality of life by causing blurry near vision, eye strain, and headaches during close-up activities. Treatment options, such as reading glasses, multifocal lenses, contact lenses, or surgical interventions like LASIK or intraocular lens implants, can help manage the condition, allowing individuals to maintain functional vision at near distances.

Presbyopia Emerging Drugs Profile

MR-141: Viatris

MR-141 is being developed by Viatris for the treatment of presbyopia. It is a 0.75% phentolamine ophthalmic solution that works by enhancing the eye’s ability to focus on near objects through muscarinic receptor targeting and mild pupil constriction. This helps expand the depth of field and improves accommodation. MR-141 is being developed in collaboration with Opus Genetics and the drug is currently in Phase III stage of its clinical trial for presbyopia.

GLK-302: Glaukos Corporation

Glaukos Corporation is developing GLK-302, a sterile ophthalmic topical cream containing pilocarpine, intended for the treatment of presbyopia. The cream is applied to the eyelid, facilitating the transdermal delivery of pilocarpine to the eye. Pilocarpine, a muscarinic acetylcholine receptor agonist, primarily targets the M3 and M1 receptors within the eye, inducing pupillary constriction and enhancing the depth of focus. This mechanism improves near vision in individuals with presbyopia while minimally affecting distance vision. The drug is currently in Phase II stage of its clinical trial for presbyopia.

The Presbyopia Pipeline Report Provides Insights into-

The report provides detailed insights about companies that are developing therapies for the treatment of Presbyopia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Presbyopia Treatment.
Presbyopia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Presbyopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Presbyopia market

Explore groundbreaking therapies and clinical trials in the Presbyopia Pipeline @ New Presbyopia Drugs

Presbyopia Companies

Viatris, Glaukos Corporation, Tenpoint Therapeutics, Vyluma and others.

Presbyopia Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Presbyopia Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn about new Presbyopia Pipeline Drugs Developments @ Presbyopia Market Drivers and Barriers

Scope of the Presbyopia Pipeline Report

Coverage- Global
Presbyopia Companies- Viatris, Glaukos Corporation, Tenpoint Therapeutics, Vyluma and others.
Presbyopia Pipeline Therapies- Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Pilocarpine HCl, UNR844-Cl, CSF-1, AGN-190584, Pilocarpine Ophthalmic, Aceclidine, Brimonidine and others.
Presbyopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Presbyopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth Presbyopia Pipeline report today! @ Presbyopia Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Presbyopia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Presbyopia – DelveInsight’s Analytical Perspective
Late Stage Products (Registration)
LNZ100: Lenz Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
GLK-302: Glaukos Corporation
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug Name: Company Name
Preclinical Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Presbyopia Collaborations Assessment- Licensing / Partnering / Funding
Presbyopia Unmet Needs
Presbyopia Market Drivers and Barriers
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/presbyopia-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/presbyopia-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Presbyopia Clinical Trial Pipeline Gains Momentum: 6+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Angelman Syndrome Clinical Trial Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Angelman Syndrome Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Angelman Syndrome pipeline landscape. It covers the Angelman Syndrome Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Angelman Syndrome Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Angelman Syndrome Pipeline? @ https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight

Key Takeaways from the Angelman Syndrome Pipeline Report

On May 15, 2026- Ionis Pharmaceuticals Inc. initiated a Phase 3 study in people with Angelman syndrome. The study will consist of 4 periods: a screening period of up to 28 days, an approximate 60-week double blind, placebo-controlled treatment period, followed by an approximate 25-month Long-Term Extension (LTE) treatment period, and an approximate 8-month Post-LTE follow-up period. The study will be comprised of 2 cohorts. Cohort 1 will include pediatric participants, aged 2 to less than (<)18 years old and serve as the population for evaluation of primary and secondary outcome measures; Cohort 2 will include adult participants, aged 18 to ≤50 years old.
On May 06, 2026- Ultragenyx Pharmaceutical Inc. conducted a phase 3 study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).
DelveInsight’s Angelman Syndrome Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Angelman Syndrome treatment.
The leading Angelman Syndrome Companies such as Neuren Pharmaceuticals, Ultragenyx Pharmaceutical, Ionis Pharmaceuticals, Roche, GEXVal, PTC Therapeutics, Taysha Gene Therapies, Ovid Therapeutics and others.
Promising Angelman Syndrome Therapies such as ION582, GTX-102, MVX-220, NNZ-2591, Alogabat, Gaboxadol, Circadin 2/5/10 mg and others.

Want to know which companies are leading innovation in Angelman Syndrome? Dive into the full pipeline insights @ Angelman Syndrome Clinical Trials Assessment

The Angelman Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Angelman Syndrome Pipeline Report also highlights the unmet needs with respect to the Angelman Syndrome.

Angelman Syndrome Overview

Angelman syndrome (AS) is a rare neuro-genetic disorder that occurs in one in 15,000 live births or 500,000 people worldwide. It is caused by a loss of function of the UBE3A gene in the 15th chromosome derived from the mother. Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs, and unique behavior with an apparent happy demeanor that includes frequent laughing, smiling, and excitability.

Angelman Syndrome Emerging Drugs Profile

NNZ-2591: Neuren Pharmaceuticals

NNZ-2591 is an analog of cyclic glycine proline, a peptide (small protein) that exists naturally in the brain and is important for the development of neurons (nerve cells). NNZ-2591 was tested in the ube3a knockout mouse model, which resembles features of Angelman syndrome in humans and includes motor deficits, learning problems and alterations in synaptic connectivity and plasticity. The study compared normal mice and “knockout mice” with a disrupted gene. In the knockout mice, treatment with NNZ-2591 for 6 weeks normalized the deficits in all the tests of anxiety, daily living, sociability, motor performance and cognition as well as eliminating seizures.

GTX-102: Ultragenyx Pharmaceutical

GTX-102 is an investigational antisense oligonucleotide (ASO) therapy designed to inhibit expression of UBE3A-AS in order to prevent silencing of the paternally inherited allele of the UBE3A gene and reactivate expression of the deficient protein. GTX-102 is delivered as an intrathecal infusion. A Phase 1/2 study evaluating the tolerability and safety of GTX-102 and its effect on all major domains of the AS in pediatric patients is currently ongoing in the U.S., U.K. and Canada.

If you’re tracking ongoing Angelman Syndrome Clinical trials, this press release is a must-read @ Angelman Syndrome Treatment Drugs

The Angelman Syndrome Pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of Angelman Syndrome with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Angelman Syndrome Treatment.
Angelman Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Angelman Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Angelman Syndrome market.

Angelman Syndrome Companies

Neuren Pharmaceuticals, Ultragenyx Pharmaceutical, Ionis Pharmaceuticals, Roche, GEXVal, PTC Therapeutics, Taysha Gene Therapies, Ovid Therapeutics and others.

Angelman Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Angelman Syndrome Products have been categorized under various Molecule types such as,

Oligonucleotide
Peptide
Small molecule

From emerging drug candidates to competitive intelligence, the Angelman Syndrome Pipeline Report covers it all @ Angelman Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Angelman Syndrome Pipeline Report

Coverage- Global
Angelman Syndrome Companies- Neuren Pharmaceuticals, Ultragenyx Pharmaceutical, Ionis Pharmaceuticals, Roche, GEXVal, PTC Therapeutics, Taysha Gene Therapies, Ovid Therapeutics and others.
Angelman Syndrome Therapies– ION582, GTX-102, MVX-220, NNZ-2591, Alogabat, Gaboxadol, Circadin 2/5/10 mg and others.
Angelman Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Angelman Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Angelman Syndrome Treatment landscape in this detailed analysis @ Angelman Syndrome Emerging Drugs and Major Players

Table of Contents

Introduction
Executive Summary
Angelman Syndrome: Overview
Pipeline Therapeutics
Therapeutic Assessment
Angelman Syndrome– DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
NNZ-2591: Neuren Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase I/II)
GTX-102: Ultragenyx Pharmaceutical
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
RG 6091: Roche
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
GT-AS: PTC Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Angelman Syndrome Key Companies
Angelman Syndrome Key Products
Angelman Syndrome- Unmet Needs
Angelman Syndrome- Market Drivers and Barriers
Angelman Syndrome- Future Perspectives and Conclusion
Angelman Syndrome Analyst Views
Angelman Syndrome Key Companies
Appendix

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/angelman-syndrome-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/angelman-syndrome-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Angelman Syndrome Clinical Trial Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Phenylketonuria (PKU) Market is Expected to Witness Significant Growth by 2036 Owing to Emerging Gene-Based and Metabolic Therapies | DelveInsight

The market dynamics for Phenylketonuria (PKU) are witnessing substantial growth driven by increasing neonatal screening programs, growing awareness regarding inherited metabolic disorders, advancements in genetic diagnostics, and the development of novel therapies aimed at improving long-term phenylalanine control. Additionally, the launch of emerging therapies such as Repinatrabit (JNT-517), AG-181, and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Phenylketonuria (PKU) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of PKU, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Phenylketonuria (PKU) Market

The market size for PKU in the leading markets is expected to grow significantly by 2036.
According to DelveInsight’s analysis, the total market size of PKU in the 7MM was approximately USD 600 million in 2022 and is projected to reach nearly USD 2.1 billion by 2036.
The United States accounted for the highest PKU market size among the 7MM in 2025 compared to EU4 countries, the United Kingdom, and Japan.
In 2025, the US recorded the highest number of diagnosed prevalent PKU cases among the 7MM, with approximately 18,000 cases. This figure is projected to rise throughout the forecast period from 2026 to 2036.
In 2025, the diagnosed prevalent cases of PKU across EU4 and the UK were approximately 32,000, with this number anticipated to grow by 2036.
In Japan, the majority of PKU cases in 2025 were reported in the under-14 age group (530 cases), while the fewest cases (40) were observed in individuals aged 45 years and older.
In 2025, the majority of severity-specific PKU cases in the US were attributed to classical PKU, accounting for nearly 10,600 reported cases.
In 2025, the highest number of mutation-specific PKU cases in Japan were associated with missense mutations (620 cases).
Leading PKU companies, such as Otsuka Pharmaceutical, Agios Pharmaceuticals, BioMarin Pharmaceutical, PTC Therapeutics, and others, are actively developing innovative therapies to improve metabolic control and address unmet clinical needs.
The promising PKU therapies in development include Repinatrabit (JNT-517), AG-181, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/phenylketonuria-pku-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Phenylketonuria (PKU) MarketIncreasing Neonatal Screening and Early Diagnosis

Widespread implementation of newborn screening programs using tandem mass spectrometry has significantly improved early diagnosis and long-term management outcomes for PKU patients.

Growing Demand for Effective Metabolic Control Therapies

Conventional dietary restrictions remain difficult to maintain lifelong. The growing need for therapies capable of sustainably reducing blood phenylalanine levels is driving demand for innovative pharmacological approaches.

Advancements in Gene-Based and Enzyme Replacement Therapies

Emerging therapeutic strategies such as enzyme substitution therapy, transporter inhibition, PAH stabilization, gene therapy, and mRNA-based approaches are expected to transform the PKU treatment landscape.

Rising Awareness Regarding Rare Genetic Disorders

Improved patient advocacy efforts, physician awareness, and rare disease research funding are accelerating diagnosis rates, treatment adoption, and pipeline innovation in PKU.

Phenylketonuria (PKU) Competitive Landscape

Several PKU therapies in development include Repinatrabit (JNT-517), AG-181, and others.
Repinatrabit (JNT-517), developed by Otsuka Pharmaceutical, is an investigational oral small-molecule therapy designed to selectively inhibit phenylalanine transport, thereby reducing systemic phenylalanine levels and improving metabolic control. The therapy is currently in Phase III development.
AG-181, developed by Agios Pharmaceuticals, is an investigational small-molecule PAH stabilizer being evaluated to regulate metabolic pathways involved in phenylalanine metabolism and improve metabolic balance in PKU patients. The therapy is currently in Phase I development.
These emerging therapies aim to improve efficacy, metabolic control, patient compliance, and long-term neurological outcomes beyond the limitations of current dietary management strategies.

Discover more about therapies set to grab major Phenylketonuria market share @ Phenylketonuria Treatment Landscape

Recent Developments in the Phenylketonuria (PKU) Market

In March 2026, Otsuka Pharmaceutical reported open-label extension data for repinatrabit (JNT-517), showing a 67% mean reduction in blood phenylalanine levels in adolescents with PKU; the data were presented at the ACMG meeting.
In February 2026, BioMarin Pharmaceutical reported that the FDA approved a supplemental Biologics License Application (sBLA) for PALYNZIQ (pegvaliase-pqpz), expanding its indication to include pediatric patients aged 12 years and older with PKU.
In December 2025, Otsuka Pharmaceutical initiated a global Phase III trial of repinatrabit (JNT-517) for PKU after receiving orphan drug and Rare Pediatric Disease Designation (RPDD) from the FDA.
In July 2025, PTC Therapeutics reported FDA approval of SEPHIENCE (sepiapterin) for PKU in patients aged ≥1 month.
In January 2026, Agios Pharmaceuticals completed dosing in the Phase I trial of AG-181 and announced plans to initiate Phase Ib studies in PKU patients during 2026.

What is Phenylketonuria (PKU)?

Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by deficiency or dysfunction of the phenylalanine hydroxylase (PAH) enzyme, resulting in the accumulation of phenylalanine in the blood and brain. Elevated phenylalanine levels can lead to severe neurological impairment, intellectual disability, developmental delay, seizures, behavioral disturbances, and psychiatric complications if left untreated.

PKU is typically diagnosed through newborn screening using tandem mass spectrometry, followed by confirmatory plasma phenylalanine testing and molecular analysis of PAH gene mutations. Current treatment focuses on maintaining safe blood phenylalanine levels through lifelong dietary management, specialized medical foods, and pharmacological therapies.

Phenylketonuria (PKU) Epidemiology Segmentation

The PKU epidemiology section provides insights into the historical and current PKU patient pool and forecasted trends for the leading markets. The PKU market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Total Diagnosed Prevalent Cases of PKU
Mutation-specific Diagnosed Prevalent Cases of PKU
Severity-specific Diagnosed Prevalent Cases of PKU
Age-specific Diagnosed Prevalent Cases of PKU

Scope of the Phenylketonuria (PKU) Market Report

Therapeutic Assessment: PKU current marketed and emerging therapies
Phenylketonuria Market Dynamics: Key Market Forecast Assumptions and Market Outlook
Key Companies: Otsuka Pharmaceutical, Agios Pharmaceuticals, BioMarin Pharmaceutical, PTC Therapeutics, and others
Key Therapies: PALYNZIQ (pegvaliase-pqpz), SEPHIENCE (sepiapterin), KUVAN (sapropterin dihydrochloride), JAVYGTOR, Repinatrabit (JNT-517), AG-181, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Phenylketonuria Market Access and Reimbursement

To know more about Phenylketonuria companies working in the treatment market, visit @ Phenylketonuria Clinical Trials and Therapeutic Assessment

Table of Contents

Phenylketonuria Market Report Introduction
Executive Summary for Phenylketonuria
SWOT Analysis of Phenylketonuria
Phenylketonuria Patient Share (%) Overview at a Glance
Phenylketonuria Market Overview at a Glance
Phenylketonuria Background and Overview
Phenylketonuria Epidemiology and Patient Population
Country-Specific Patient Population of Phenylketonuria
Phenylketonuria Current Treatment and Medical Practices
Phenylketonuria Unmet Needs
Phenylketonuria Emerging Therapies
Phenylketonuria Market Outlook
Country-Wise Phenylketonuria Market Analysis (2022–2036)
Phenylketonuria Market Access and Reimbursement of Therapies
Phenylketonuria Market Drivers
Phenylketonuria Market Barriers
Phenylketonuria Appendix
Phenylketonuria Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Phenylketonuria (PKU) Market is Expected to Witness Significant Growth by 2036 Owing to Emerging Gene-Based and Metabolic Therapies | DelveInsight

Schizophrenia Market is Expected to Expand Significantly by 2036 Owing to Rising Disease Burden and Launch of Novel Antipsychotic Therapies | DelveInsight

The Schizophrenia market is witnessing growth due to the rising prevalence of schizophrenia, increasing mental health awareness, advancements in psychiatric research, and the adoption of long-acting injectable therapies. Moreover, emerging therapies such as olanzapine LAI (TEV-’749), ulotaront (SEP-363856), brilaroxazine (RP-5063), roluperidone (MIN-101/MT-210), and evenamide (NW-3509) are expected to further boost market growth.

The market dynamics for Schizophrenia are witnessing substantial growth driven by the increasing prevalence of schizophrenia, rising awareness regarding mental health disorders, advancements in psychiatric research, growing adoption of long-acting injectable therapies, and the development of novel antipsychotic agents with improved efficacy and safety profiles. Additionally, the launch of emerging therapies such as olanzapine LAI (TEV-’749), ulotaront (SEP-363856), brilaroxazine (RP-5063), roluperidone (MIN-101/MT-210), evenamide (NW-3509), and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Schizophrenia Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Schizophrenia, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Schizophrenia Market

The market size for Schizophrenia in the leading markets is expected to grow significantly by 2036.
The schizophrenia market size in the 7MM was more than USD 8 billion in 2025 and is further expected to increase by 2036.
Among the 7MM, the United States accounted for the largest schizophrenia market size in 2025 with nearly USD 6 billion, compared to EU4 countries, the United Kingdom, and Japan.
DelveInsight’s analysis suggests that in 2025 the total diagnosed prevalent cases of schizophrenia in the 7MM were nearly 4 million cases, of which the US accounted for approximately 1.5 million cases.
Among EU4 and the UK, nearly 42% of the total diagnosed prevalent schizophrenia cases were reported in 2025.
According to DelveInsight’s analysis, males are more susceptible to schizophrenia due to genetic, hormonal, and neurodevelopmental factors. In 2025, the diagnosed prevalence in the US was approximately 780,000 for males and 670,000 for females.
In 2025, Germany accounted for nearly 450,000 diagnosed prevalent cases of schizophrenia, representing the highest burden among EU4 countries and the UK.
In 2025, Japan accounted for approximately 1 million prevalent cases of schizophrenia, of which nearly 790,000 were diagnosed.
According to WHO, nearly 50% of mental hospital patients globally have schizophrenia, but only 31.3% of those with psychosis receive specialized care.
Leading schizophrenia companies, such as Teva Pharmaceutical Industries, Otsuka Pharmaceuticals, Sumitomo Pharma, Reviva Pharmaceuticals, Minerva Neurosciences, Newron Pharmaceuticals, Bristol Myers Squibb, and others, are developing novel schizophrenia therapies to improve treatment outcomes and address unmet needs.
The promising schizophrenia therapies in development include olanzapine LAI (TEV-’749), ulotaront (SEP-363856), brilaroxazine (RP-5063), roluperidone (MIN-101/MT-210), evenamide (NW-3509), and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Schizophrenia Market

Rising Disease Prevalence and Awareness:- Increasing awareness regarding schizophrenia, improvements in psychiatric diagnosis, and reduction in social stigma associated with mental health disorders are contributing to greater diagnosis and treatment rates globally.
Increasing Adoption of Long-Acting Injectable Therapies: – Long-acting injectable (LAI) therapies are gaining traction due to improved patient adherence, reduced relapse rates, and enhanced long-term symptom control compared to oral therapies.
Growing Demand for Novel Mechanism-Based Therapies: – Current antipsychotics primarily target dopamine pathways but are often associated with metabolic side effects and limited efficacy against negative and cognitive symptoms. Emerging therapies targeting TAAR1, glycine transporters, serotonin receptors, and glutamate pathways are expected to transform the schizophrenia treatment landscape.
Advancements in Personalized and Holistic Care Approaches: – Psychosocial interventions, cognitive behavioral therapy, supported employment programs, digital psychiatry solutions, and patient-centered care models are increasingly being integrated into schizophrenia management.

Schizophrenia Competitive Landscape

Several schizophrenia drugs in development include olanzapine LAI (TEV-’749), ulotaront (SEP-363856), brilaroxazine (RP-5063), roluperidone (MIN-101/MT-210), evenamide (NW-3509), and others.
These candidates target diverse mechanisms such as TAAR1 agonism, serotonin-dopamine modulation, sigma receptor antagonism, glutamatergic modulation, and long-acting injectable delivery systems to improve efficacy, adherence, and management of both positive and negative symptoms of schizophrenia.

Discover more about therapies set to grab major Schizophrenia market share @ Schizophrenia Treatment Landscape

Recent Developments in the Schizophrenia Market

In September 2024, the US FDA approved Bristol Myers Squibb’s COBENFY (xanomeline and trospium chloride) for the treatment of schizophrenia in adults, representing the first novel schizophrenia mechanism in decades without D2 receptor blockade.
In February 2026, the US FDA accepted Teva Pharmaceutical Industries’ NDA for olanzapine extended-release injectable suspension (TEV-’749), intended for once-monthly schizophrenia treatment in adults.
In January 2026, Reviva Pharmaceuticals announced publication of clinical vocal biomarker data from the RECOVER Phase III trial evaluating brilaroxazine in schizophrenia patients.
In October 2025, Minerva Neurosciences secured financing of up to USD 200 million to support the Phase III confirmatory trial and regulatory advancement of roluperidone for schizophrenia negative symptoms.
In July 2023, Sumitomo Pharma and Otsuka reported Phase III DIAMOND trial results for ulotaront (SEP-363856), while Otsuka continued Phase III development activities in the US.

What is Schizophrenia?

Schizophrenia is a severe chronic mental disorder that affects thinking, emotions, perception, decision-making, and social functioning. The disease commonly manifests during late adolescence or early adulthood and is characterized by psychotic symptoms including hallucinations, delusions, disorganized thinking, negative symptoms, and cognitive impairments.

The diagnosis of schizophrenia involves psychiatric evaluation, clinical interviews, exclusion of other psychiatric or neurological disorders, and assessment tools such as PANSS, CGI, and SANS scales to evaluate symptom severity. Treatment generally involves pharmacotherapy, psychosocial interventions, counseling, behavioral therapy, and social support programs aimed at improving long-term patient functioning and quality of life.

Schizophrenia Epidemiology Segmentation

The Schizophrenia epidemiology section provides insights into the historical and current schizophrenia patient pool and forecasted trends for the leading markets. The schizophrenia market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Total Prevalent Cases of Schizophrenia
Total Diagnosed Prevalent Cases of Schizophrenia
Gender-specific Diagnosed Prevalent Cases of Schizophrenia
Severity-specific Diagnosed Prevalent Cases of Schizophrenia
Age-specific Diagnosed Prevalent Cases of Schizophrenia

Scope of the Schizophrenia Market Report

Therapeutic Assessment: Schizophrenia current marketed and emerging therapies
Schizophrenia Market Dynamics: Key Market Forecast Assumptions and Market Outlook
Key Companies: Teva Pharmaceutical Industries, Otsuka Pharmaceuticals, Sumitomo Pharma, Reviva Pharmaceuticals, Minerva Neurosciences, Newron Pharmaceuticals, Bristol Myers Squibb, and others
Key Therapies: COBENFY, olanzapine LAI (TEV-’749), ulotaront (SEP-363856), brilaroxazine (RP-5063), roluperidone (MIN-101/MT-210), evenamide (NW-3509), REXULTI, CAPLYTA, VRAYLAR, LATUDA, INVEGA products, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Schizophrenia Market Access and Reimbursement

To know more about Schizophrenia companies working in the treatment market, visit @ Schizophrenia Clinical Trials and Therapeutic Assessment

Table of Contents

Schizophrenia Market Report Introduction
Executive Summary for Schizophrenia
SWOT Analysis of Schizophrenia
Schizophrenia Patient Share (%) Overview at a Glance
Schizophrenia Market Overview at a Glance
Schizophrenia Background and Overview
Schizophrenia Epidemiology and Patient Population
Country-Specific Patient Population of Schizophrenia
Schizophrenia Current Treatment and Medical Practices
Schizophrenia Unmet Needs
Schizophrenia Emerging Therapies
Schizophrenia Market Outlook
Country-Wise Schizophrenia Market Analysis (2022–2036)
Schizophrenia Market Access and Reimbursement of Therapies
Schizophrenia Market Drivers
Schizophrenia Market Barriers
Schizophrenia Appendix
Schizophrenia Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schizophrenia Market is Expected to Expand Significantly by 2036 Owing to Rising Disease Burden and Launch of Novel Antipsychotic Therapies | DelveInsight

ISDN’s IDI Dynamics Debuts High-Speed Laser Marker for Semiconductor Assembly and Test (OSAT)

New High-speed Laser Marker delivers 2.5x higher chip throughput (units per hour) in a 22% smaller footprint, helping Outsourced Semiconductor Assembly & Test (OSAT) manufacturers drive productivity of valuable production floor space.

IDI Dynamics, a subsidiary of ISDN Holdings Limited (SGX: I07 / 1656.HK), has launched its next generation High-speed Laser Marker for semiconductor chip packages, with a dual value proposition of delivering 2.5x higher marking speed and occupying 22% less physical footprint.

The IDI Laser Marker launches with 6 OSAT deployments throughout Asia, and leverages advanced technology contributed by:

– The pre-eminent public research institution in Singapore for industrial research; and

– ISDN Holding’s 20-year experience in providing automation engineering and systems for the semiconductor industry.

In head-to-head evaluations against widely deployed industry configurations, the IDI Laser Marker achieves marking speeds up to 2.5 times faster, delivering substantially higher units per hour, while occupying 22 percent less cleanroom floor space. The gains are based on benchmarking using representative OSAT strip formats and standard mark content, with cycle time measured end to end including strip handling.

By increasing marking speed and decreasing floor space, IDI’s Laser Market delivers a 3.2x increase in marking productivity per square foot. Floor space has become a critical issue for the semiconductor industry in light of both:

– The rapid growth in demand for chips as a result of AI adoption; and

– The rapidly-rising costs of constructing new clean room factories necessary for producing advanced semiconductor chips.

As a result, IDI has delivered a next-generation marking system aimed at maximising the manufacturing productivity of valuable existing clean room space.

The Laser Marking platform also responds to widening traceability requirements in automotive and industrial electronics, where permanent laser marking is increasingly mandatory. Every system includes a two-year software customisation and support programme covering factory automation integration, handling adaptation, and evolving compliance coding.

“We developed the advanced IDI Laser Marker because our OSAT customers told us that floor space and throughput are now fundamentally integrated, as manufacturers look to maximise output with the smallest economical floor footprint,” said Chris Chan, Managing Director of IDI Dynamics. “Our new Laser Marking platform is already delivering this value proposition of the 6 units at launch, and we are pleased to be on the forefront of enabling the next generation of advanced chip manufacturing in the global market”.

Mr. Teo Cher Koon, Managing Director and President, added that “IDI’s Laser Marking solution is an example of how ISDN’s ‘full stack’ approach to technology and 30 years of serving the semiconductor industry can create powerful collaboration to bring advanced technology to our customers throughout Asia. The IDI Laser Marker product combines cutting-edge research from a pre-eminent research institution with ISDN’s decades-long experience with semiconductor and OSAT customers, and a focused entrepreneurial team at our IDI Dynamics subsidiary to bring compelling innovation into the semiconductor market at a time when the industry needs help scaling manufacturing productivity to meet skyrocketing demand.

IDI Dynamics is part of a broad range of strategic solutions that ISDN builds and deploys in the semiconductor industry today, ranging from critical components to full systems and products like the Laser Market today. Our semiconductor solutions are amongst most exciting and fast-growing businesses at ISDN Holdings today.”

About IDI Dynamics

IDI Dynamics is a subsidiary of ISDN Holdings Limited (SGX: I07 / 1656.HK) and is headquartered in Singapore, Supporting OSAT manufacturers across Southeast Asia and Globally. Further technical specifications and performance benchmarks for the Strip Marker platform are available upon request.

About ISDN Holdings

ISDN is a leading provider of industrial automation solutions throughout Asia, serving more than 10,000 customers through 55 sales offices spanning key Asian growth markets. Founded in 1986, ISDN has a 39-year track record supporting advanced industries including semiconductors, aerospace, medical devices, clean energy, and intelligent manufacturing.

ISDN has been listed on the SGX Main Board since 2005 and the Hong Kong Stock Exchange Main Board since 2017.

For more information, please visit www.isdnholdings.com.

Issued for and on behalf of ISDN Holdings Limited by Financial PR.

For media enquiries, please contact:

Kamal SamuelEmail: kamal@financialpr.com.sg

Vicki ZhouEmail: zhouyan@financialpr.com.sg

Louise LimEmail: louise@financialpr.com.sg

Tel: +65 6438 2990

Business enquiries — request a performance simulation or live demo:

What they’ll receive: (1) an indicative throughput and cycle‑time assessment for their strip format and mark content; (2) a footprint comparison and layout recommendation for their line; and (3) an integration checklist covering automation interface, handling adaptation, and traceability code requirements.

Media Contact
Company Name: IDI Dynamics
Contact Person: Media Relations
Email: Send Email
Phone: +65 9617 6289
Country: Singapore
Website: https://idilaser.com/

Acute Liver Failure Market is Anticipated to Grow by 2036 Owing to Rising Incidence of Drug-Induced Liver Injury and Emerging Regenerative Therapies | DelveInsight

The market dynamics for Acute Liver Failure (ALF) are witnessing steady growth driven by the rising incidence of drug-induced liver injury, increasing acetaminophen toxicity cases, growing burden of viral hepatitis-associated liver failure, and advancements in supportive critical care management. Additionally, the emergence of innovative regenerative therapies such as SBL01 (SeaBeLife) and bbHEP01 (bit.bio) is expected to create future growth opportunities in the ALF market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Acute Liver Failure (ALF) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Acute Liver Failure, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Acute Liver Failure Market

The market size for Acute Liver Failure in the leading markets is expected to increase significantly by 2036.
According to DelveInsight’s analysis, the total market size of ALF in the 7MM was approximately USD 3,726 million in 2022 and is projected to reach nearly USD 5,874 million by 2036.
The United States accounted for the highest Acute Liver Failure treatment market size in 2025 compared to EU4 countries, the United Kingdom, and Japan.
ALF is a rare yet life-threatening condition, with approximately 3,000 cases reported annually in North America, accounting for nearly 4–5% of all liver transplants.
Drug-induced liver injury (DILI) was found to be responsible for nearly 50% of ALF cases in the US, with acetaminophen toxicity being the leading cause.
In the UK, paracetamol toxicity accounts for nearly 65% of ALF cases.
In Japan, hepatitis B virus infection is the primary cause of ALF, responsible for approximately 40% of cases.
In Germany, the incidence of ALF was estimated at 1.22 per 100,000 person-years, with females accounting for 53% of cases.
Leading Acute Liver Failure companies, such as SeaBeLife and bit.bio, are developing emerging ALF therapies to address the high unmet need in this space.
The promising Acute Liver Failure therapies in development include SBL01 and bbHEP01.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/acute-liver-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Acute Liver Failure MarketRising Incidence of Drug-Induced Liver Injury and Acetaminophen Toxicity

Drug-induced liver injury remains the leading cause of Acute Liver Failure globally. Increasing use of prescription medications, over-the-counter drugs, dietary supplements, and substance abuse contribute significantly to the rising burden of ALF cases.

Increasing Burden of Viral Hepatitis-Associated ALF

Viral hepatitis, especially hepatitis B, continues to contribute substantially to ALF incidence in several regions, particularly Japan and developing countries, thereby driving demand for improved therapeutic management.

Growing Need for Effective Disease-Modifying Therapies

Currently, no approved targeted pharmacological therapies are available for ALF. Management primarily relies on supportive care and liver transplantation, highlighting the urgent need for novel regenerative and hepatoprotective therapies.

Advancements in Critical Care and Liver Support Systems

Improvements in intensive care management, intracranial pressure management, liver support systems, and transplantation protocols are enhancing patient survival and expanding treatment access.

Acute Liver Failure Competitive Landscape

Several companies are evaluating novel approaches for Acute Liver Failure treatment, including SeaBeLife and bit.bio.
The emerging ALF therapies include SBL01 and bbHEP01.
SBL01 is a first-in-class small molecule designed to inhibit necroptosis and ferroptosis, thereby protecting hepatocytes and supporting liver regeneration.
bbHEP01 utilizes encapsulated allogeneic hepatocyte-like cells developed using cell programming technology to provide temporary liver support and bridge patients to transplantation or spontaneous liver recovery.

Discover more about therapies set to grab major Acute Liver Failure market share @ Acute Liver Failure Treatment Landscape

Recent Developments in the Acute Liver Failure Market

In September 2024, the EMA granted orphan drug designation to SeaBeLife’s SBL01 for the treatment of Acute Liver Failure.
bit.bio announced that bbHEP01 is expected to initiate clinical trials in 2025, with preliminary clinical results anticipated in 2026.
The ALF treatment pipeline remains limited, highlighting substantial opportunities for innovation and development of disease-modifying therapies.

What is Acute Liver Failure?

Acute Liver Failure (ALF), also known as fulminant hepatic failure, is characterized by the sudden onset of severe liver dysfunction due to rapid liver cell death or injury in patients without preexisting liver disease. The American Association for the Study of Liver Diseases (AASLD) defines ALF as the presence of coagulation abnormalities, usually an international normalized ratio (INR) above 1.5, along with any degree of hepatic encephalopathy occurring within less than 26 weeks of illness onset.

ALF may result from multiple causes including acetaminophen overdose, drug-induced liver injury, viral hepatitis, autoimmune hepatitis, Wilson’s disease, vascular injury, and metabolic disorders. Symptoms often begin with fatigue, nausea, vomiting, and abdominal discomfort, followed by jaundice, encephalopathy, cerebral edema, coagulopathy, and multiorgan failure.

Acute Liver Failure Epidemiology Segmentation

The Acute Liver Failure epidemiology section provides insights into the historical and current ALF patient pool and forecasted trends for the leading markets. The Acute Liver Failure market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Total Incident Cases of Acute Liver Failure
Gender-specific Cases of Acute Liver Failure
Age-specific Cases of Acute Liver Failure
Etiology-specific Cases of Acute Liver Failure
Treated Cases of Acute Liver Failure

Scope of the Acute Liver Failure Market Report

Therapeutic Assessment: Acute Liver Failure current and emerging therapies
Acute Liver Failure Market Dynamics: Key Market Forecast Assumptions and Market Outlook
Key Companies: SeaBeLife, bit.bio, and others
Key Therapies: SBL01, bbHEP01, N-acetylcysteine (NAC), supportive care therapies, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Acute Liver Failure Market Access and Reimbursement

To know more about Acute Liver Failure companies working in the treatment market, visit @ Acute Liver Failure Clinical Trials and Therapeutic Assessment

Table of Contents

Acute Liver Failure Market Report Introduction
Executive Summary for Acute Liver Failure
SWOT Analysis of Acute Liver Failure
Acute Liver Failure Patient Share (%) Overview at a Glance
Acute Liver Failure Market Overview at a Glance
Acute Liver Failure Background and Overview
Acute Liver Failure Epidemiology and Patient Population
Country-Specific Patient Population of Acute Liver Failure
Acute Liver Failure Current Treatment and Medical Practices
Acute Liver Failure Unmet Needs
Acute Liver Failure Emerging Therapies
Acute Liver Failure Market Outlook
Country-Wise Acute Liver Failure Market Analysis (2022–2036)
Acute Liver Failure Market Access and Reimbursement of Therapies
Acute Liver Failure Market Drivers
Acute Liver Failure Market Barriers
Acute Liver Failure Appendix
Acute Liver Failure Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Liver Failure Market is Anticipated to Grow by 2036 Owing to Rising Incidence of Drug-Induced Liver Injury and Emerging Regenerative Therapies | DelveInsight

Tax Expert Carrie Kiser of Kiser Tax and Accounting in Tempe, Arizona, Co-Authors New Bestselling Tax Reduction Book for Small Business Owners Entitled “DeTaxify Your Life”

“I work with small business owners to uncover tax strategies they didn’t know existed, the same proactive approach I share in “DeTaxify Your Life” to help reduce tax liability and improve cash flow.” – Carrie Kiser, Kiser Tax and Accounting

Carrie Kiser, a Phoenix, Arizona area, tax accountant, Enrolled Agent, and business tax consultant at Kiser Tax and Accounting in Tempe, co-authors a bestselling book, “DeTaxify Your Life,” focusing on proactive tax planning, tax reduction strategies, bookkeeping, and small business tax services. Known for providing strategic planning, tax preparation, and year-round implementation, Kiser helps entrepreneurs reduce tax liability, improve cash flow, and achieve stronger financial results.

Tempe, AZ – Carrie Kiser, a leading tax accountant in Tempe, AZ, business tax consultant, and founder of Kiser Tax & Accounting, has reached #1 bestseller status as a co-author of the newly released book, “DeTaxify Your Life: Trim the Fat from Your Tax Bill and Put More Money in Your Pocket.” Kiser is widely known for providing proactive tax planning services that help small business owners reduce tax burdens and increase profitability.

Released on April 16, 2026, the book surged to bestseller status and the #1 spot on Amazon’s Taxation, Bookkeeping, and Small Business Taxes lists on its first day. The collaboration features 17 of the country’s premier Certified Tax Coaches, each sharing proactive frameworks designed to help small business owners, entrepreneurs, and individuals to potentially save thousands of dollars on their taxes.

The book addresses a critical gap in the market: while most small business owners rely on “rearview mirror” tax preparation, this guide provides a proactive roadmap to legally and significantly lower tax liabilities before the year ends across a variety of different areas.

“Business owners looking for tax help don’t often realize how much they’re leaving on the table,” says Carrie Kiser of Kiser Tax and Accounting. “With proactive tax planning, we help clients uncover opportunities to reduce taxes and improve cash flow year-round,” Carrie Kiser added.

In her contribution, Kiser draws on her experience as a Certified Tax Coach and Enrolled Agent in Tempe, Arizona, to simplify complex financial challenges for business owners and individuals. Her work reflects the same proactive approach she delivers through her tax planning, preparation, and bookkeeping services at Kiser Tax and Accounting.

The book covers key topics, including Modern Reform Strategies: Navigating the most recent legislative changes, including the One Big Beautiful Bill Act. Proactive Planning: How to avoid the common compliance mistakes that lead to overpayment. Overlooked Strategies and Deductions: Identifying legal paths to maximize tax-free income.

“DeTaxify Your Life” is now available for purchase on Amazon.

About Carrie Kiser

Carrie Kiser is a Certified Tax Coach and Accredited Small Business Consultant who founded Kiser Tax and Accounting to provide proactive accounting support, advice, and strategies that help small business owners keep more of what they earn while working toward their individual definitions of success.

Since 2017, Carrie’s life’s work has been to educate and empower entrepreneurs to take control of their finances, highlighting their strengths while identifying areas for improvement. She and her team design customized tax strategies and implement them through year-round bookkeeping support, as needed, to provide direction and accountability.

For more information please visit:

Google Maps/Profile

Amazon

Media Contact
Company Name: Kiser Tax and Accounting
Contact Person: Carrie Kiser, Certified Tax Coach
Email: Send Email
Phone: (480) 712-8122
Address:4450 S Rural Rd E225 Tempe, AZ 85282, USA
City: Tempe
State: Arizona
Country: United States
Website: https://kiser.tax/

Liz Carroll’s New Book, Rich & Radiant, Featured in Special Amazon Flash Sale

Liz Carroll, Master Financial Coach, Certified Life Coach, yoga and meditation instructor, and founder of the Mindful Money Method, announces a special Amazon Flash Sale for her new book, Rich & Radiant: The High-Performing Woman’s Guide to Freedom, Fulfillment, and a New Definition of Wealth.

Written for high-achieving women who appear successful on the outside but still feel uncertain, disconnected, or anxious about money, Rich & Radiant offers a compassionate and practical path toward financial calm, confidence, and intentional living. Carroll guides readers through a holistic approach to money that blends math, mindset, and mindfulness, helping women move from avoidance and fear to awareness, clarity, and vision.

“Many women are earning well, achieving a lot, and still quietly wondering if they are doing it right,” says Carroll. “This book is an invitation to stop living on financial autopilot and begin creating a relationship with money that feels calm, aligned, and empowering.”

In Rich & Radiant, Carroll teaches women how to face their “math of the moment,” build financial safety nets, rewrite limiting money stories, define their own financial independence number, and align their money with what matters most to them. The book also explores how fear, guilt, comparison, and old inherited beliefs can quietly shape financial decisions, and how women can replace those patterns with self-trust, clarity, and mindful action.

At the heart of the book is Carroll’s belief that wealth is more than accumulation. True wealth includes freedom, fulfillment, generosity, emotional wellness, meaningful experiences, and the ability to live with intention. Through personal stories, client examples, practical exercises, and empowering reframes, Rich & Radiant helps readers create a financial life that supports who they are becoming.

“This is not a book about restriction or shame,” Carroll says. “It is about helping women feel safe enough to look honestly at their money, powerful enough to make aligned decisions, and free enough to live richly and radiantly right now, not someday.”

Don’t miss your chance to grab Rich & Radiant at a special price during the Amazon Flash Sale: https://www.amazon.com/dp/B0H1NHBMTH

Learn more about Liz Carroll and her workshops at: www.BeRichandRadiant.com.

About Liz Carroll

Liz Carroll is a lifelong student and teacher of making mindful money moves. Once believing she was “bad with money,” Liz did the work to rewrite her money story, releasing limiting beliefs about how a woman can earn, spend, and save. That shift led her to financial independence and an early retirement from her corporate IT sales career.

Now, in her encore career, Liz helps women experience calm confidence with their finances by unpacking and transforming their own money stories. She brings order to chaos and clarity to confusion, illuminating the emotional side of personal finance with compassion and wisdom. Through her signature Mindful Money Method, a holistic blend of math, mindset, and mindfulness, Liz guides women toward lasting change through small, consistent actions that create freedom and fulfillment.

Liz is a Master Financial Coach (Ramsey Solutions), Certified Life Coach (The Life Coach School), and 200-RYT Yoga & Meditation Instructor (Purna Yoga College). She lives on the Oregon Coast with her husband, where their adult children and grandchildren visit often.

Media Contact
Company Name: Imperial Action
Contact Person: Media Manager
Email: Send Email
Phone: (630) 923-5425
Country: United States
Website: http://imperialaction.com

Virtual Reality Technology to Help People in Arkansas With Their Mental Health

An Arkansas mental health clinic is using virtual reality to help people reduce their stress levels and regulate their emotions.

PsychologyWorks PLLC, which is based in Bentonville, Northwest Arkansas, has officially partnered with Healium, a VR‑based biofeedback platform used in clinical, medical, and high‑performance settings. People will be able to experience immersive VR environments, which respond to how they are feeling using real-time physiological data like their heart rate and heart rate variability.

The clinic is the only setting in Arkansas which offers this technology, other than Veterans Affairs (VA). And PsychologyWorks will be integrating Healium into its psychotherapy for emotional regulation, trauma stabilization and neurodivergent‑affirming care.

Licensed clinical psychologist Dr Stephanie Steele-Wren is the founder and owner of PsychologyWorks and believes the technology will be highly effective in helping people deal with stress. She says: “Healium is basically a way to make your nervous system visible. You put on a VR headset and a small wearable that reads your heart rate and your HRV.

“As your physiology shifts even slightly, the VR environment shifts with you. If you settle, breathe, or ground, the scene calms with you. If your stress rises, the environment reflects that too.”

And Dr Steele-Wren, who specializes in working with neurodivergent people, says the technology is extremely helpful for those who may find it difficult to identify or describe how they are feeling.

She adds: “It takes something most people cannot feel or describe, their internal state, and turns it into something they can literally watch change in front of them. For neurodivergent clients, trauma survivors, kids, teens, and adults who do not regulate through talking alone or even at all, this is huge.”

There have been multiple published studies, including research carried out with Mayo Clinic into the value of using virtual reality to reduce stress levels and anxiety. Researchers found the technology reduced people’s stress markers, improved their HRV and helped decrease distress quickly.

Dr Steele-Wren says: “Bringing this into PsychologyWorks felt like the right move for the community I serve. Healium is backed by research and what matters to me clinically is how accessible it is. It meets people where they actually are, sensorily, visually and experientially.”

For more details on PsychologyWorks, visit www.psychologyworkspllc.com and to find out about Healium, visit www.tryhealium.com

Media Contact
Company Name: Dauntless PR
Contact Person: Luana Ribeira
Email: Send Email
Phone: 03300434102
Country: United Kingdom
Website: http://dauntlesspr.com

Healing with Sacred Geometry – Amanda Slade Newly Released Book Offers a Highly Effective Spiritual Transformation Framework

Long Beach, CA, USA – May 28, 2026 – Renowned Transformation Expert, Spiritual Mentor, and best-selling author Amanda Slade has officially released her new book, A 30-Day Soul’s Journey: Your Path of Awakening—a powerful 30-day transformational guide designed to help readers awaken, heal, and align with their Soul’s purpose, plan, and path so they can operate, create, and live from a higher level of awareness, understanding, and conscious choice.

Rooted in Amanda’s internationally recognized The Diamond Co-Creative System®—a 25-year, tried-and-proven transformational energy technology—this immersive journey offers readers a practical, spiritually grounded pathway to move from survival, self-doubt, and unconscious patterns into embodied transformation, conscious living, and personal and professional evolution.

Through four progressive phases—Transformation, Alignment, Manifestation, and Expansion—readers are guided one day at a time through spiritual principles, energetic awareness, powerful reflections, Soul-guided insights, and Amanda’s signature Diamond Co-Creation Codes, all designed to support deep healing, inner coherence, and measurable life transformation and results.

“For many people, awakening begins when what once worked no longer aligns with who they are becoming,” says Slade. “This book was created for the moment when your Soul becomes louder than old programming, limiting beliefs, and survival-based patterns.”

A 30-Day Soul’s Journey helps readers turn awakening into 5th Dimensional living—a new way of being, living, leading, and creating through the flow of Love, joy, creativity, prosperity, intuition, and Soul alignment.

For more than 25 years, Amanda Slade has helped thousands of seekers, entrepreneurs, creatives, coaches, healers, executives, leaders, and visionaries heal and transform energetic blocks and patterns, manifest Soul-aligned outcomes, and step into greater purpose, fulfillment, prosperity, leadership, and legacy.

In addition to being a best-selling author and the creator of The Diamond Co-Creative System®, Amanda is featured in the Pillars of Power movie alongside Dr. Joe Vitale, John Assaraf, Lisa Nichols, and other thought leaders from The Secret, sharing insights on transformation, vibrational alignment, and the deeper spiritual principles behind extraordinary success.

Amanda Slade is available for interviews.

A 30-Day Soul’s Journey: Your Path of Awakening is now available on Amazon.com.

Book Preview: https://mybook.to/a30DaySoulsJourney

About Amanda Slade: https://cocreateyoursuccess.com/aboutamanda

Media Contact
Company Name: Co-Create Your Success
Contact Person: Amanda Slade
Email: Send Email
Phone: 415-426-9764
Country: United States
Website: https://cocreateyoursuccess.com